Dr. Neal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000Fax+1 650-498-5840
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004 - 2007
Northwestern University The Feinberg School of MedicineClass of 2004
Certifications & Licensure
CA State Medical License 2010 - 2025
MA State Medical License 2006 - 2011
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations Start of enrollment: 2009 Oct 01
- A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Start of enrollment: 2011 Jun 01
- Molecular Analysis of Thoracic Malignancies Start of enrollment: 2011 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- A Phase 2 Single-Arm Trial of High-Dose Precision Targeted Radiation Therapy Added to Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer.Michael F Gensheimer, Nikhil V Kotha, Lucas K Vitzthum, Alexander L Chin, Scott Jackson
International Journal of Radiation Oncology, Biology, Physics. 2025-03-01 - Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis.Yuhsin Vivian Huang, Yin Sun, Harrison Chou, Noah Wagner, Maria Rosaria Vitale
Circulation Research. 2025-02-11 - Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembr...Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo, David J Pinato
Journal for Immunotherapy of Cancer. 2025-02-04
Lectures
- Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Other
- Personalized, genotype-directed therapy for advanced non-small cell lung cancerNeal JW, Sequist LV
http://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-
UpToDate, Wolters Kluwer Health - 2013-02-25
Press Mentions
Exelixis Announces Results from COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Multiple Advanced Solid Tumor TypesMay 13th, 2020
Sequencing Switches, Intriguing Combos Being Debated in ALK+ NSCLCAugust 8th, 2017- Presents State of the Science Summit™: Updates in Management of Adenocarcinoma of the LungJune 12th, 2017
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
